Tuesday, 12 April 2016 10:31

Glaxo’s Potential Cure for “Bubble Boy Disease” One Step Closer

Written by 
Rate this item
(1 Vote)

Glaxo’s Potential Cure for “Bubble Boy Disease” One Step Closer

A potential cure for children born with a form of an extremely rare immune-system condition often referred to as “bubble-boy disease” has moved a step closer to approval after receiving the support of a European Union regulatory panel.


The treatment, which involves inserting a new gene into the patient’s stem cells, received a positive opinion from the European Medicines Agency’s advisory committee on Friday, paving the way for final approval in coming months.

It is aimed at children with a disease known as ADA-SCID, a rare condition in which a single genetic defect prevents sufferers from developing a robust immune system, leaving them very susceptible to infections. Without treatment, they rarely live for more than two years.

Currently, the best available option is a bone-marrow transplant, but success heavily depends on how well matched the donor is. For the one in four babies who have a well matched family member, a transplant can be an effective cure. But for the rest, success rates can be as low as 50%, according to Bobby Gaspar,professor of pediatrics and immunology at London’s Great Ormond Street Hospital.

The new therapy, called Strimvelis, was developed by a group of scientists and doctors based in Milan who have used it to treat 22 children over the past 14 years. All are still alive, most without needing any further treatment. In 2010, GlaxoSmithKline PLC struck a licensing deal for the rights to market the therapy.

If approved, it would be only the second gene therapy to be sold in Europe, after UniQure NV’s Glybera for a rare genetic condition in which the body can’t break down fat molecules. No gene therapies are approved for sale in the U.S.

The ADA-SCID gene therapy has moved at a cautious pace. Scientists tested an older form of gene therapy in children with the disease as early as 1990, but suffered a setback when, around 10 years later, several of those patients developed a leukemia-like condition.

“To be recognized as a licensed medicine shows gene therapy has come a long way forward,” Dr. Gaspar said.

One complication of administering Strimvelis: For now, it can be performed only in the Milan hospital where it was developed. The procedure involves removing some stem cells from the patient, applying the gene therapy outside the body and then reinjecting them, all of which must be done in quick succession to keep within the short “shelf life” of stem cells.

Parents will probably be willing to take their babies to Milan for treatment if it is considered the best option: Children from as far away as the U.S. and the Middle East came to Italy to take part in the clinical trial, according to Martin Andrews, head of the company’s rare-disease unit. Still, Glaxo aims to eventually make the therapy available in several “hubs,” and is working on methods to increase the shelf life of stem cells so that the procedure could be done remotely, by sending the child’s stem cells to a central facility for the gene therapy, he said. Glaxo also plans to seek approval from America’s Food and Drug Administration in 2017.

While Strimvelis is unlikely to move the needle for Glaxo in terms of revenue—around 14 babies are born with the condition every year in Europe—the company is betting that the technology can be used as the basis for several new treatments, Mr. Andrews said.

Rare diseases have drawn increasing interest from drugmakers in the past few years because the industry can command high prices for effective treatments in diseases with few other available therapies.

“If efficacy is demonstrated, payers are willing to reimburse [the companies],” said Mladen Tomich, head analyst for rare diseases at health-care consultancy Decision Resources Group. “While the price tag is high the overall expenditures are still limited due to the small patient population.”

Mr. Andrews didn’t disclose Glaxo’s pricing plans for the treatment but said it was considering flexible pricing models, including amortizing the payment over several years.



Read 267221 times Last modified on Tuesday, 12 April 2016 10:52

Latest from [email protected]


  • Comment Link smoking Thursday, 30 March 2017 08:38 posted by smoking

    It has been about 10 days noww since he started utilising
    the Clove cigarette owner and each every now and then, either
    very first thing eah day or after dinner, he craves the total puch of having a cigarette so he's got smoked about 4 without the filter.

  • Comment Link used porsche for sale Thursday, 30 March 2017 08:37 posted by used porsche for sale

    The unit, FiberNet, delivers telecommunications companies in Florida,
    Texas and elements of South Central United States.

  • Comment Link here you go Thursday, 30 March 2017 08:37 posted by here you go

    Very good article friend, keep up the good work, just shared this
    with my buddies

  • Comment Link Ellis Thursday, 30 March 2017 08:33 posted by Ellis

    You're so awesome! I do not think I can learn something like this before.
    So excellent to find someone with some unique ideas
    on this subject. really thanks for bringing this up.
    this website is something that is needed on the net,
    somebody with somewhat creativity. excellent job for bringing something new to the web!

  • Comment Link source for article Thursday, 30 March 2017 08:25 posted by source for article

    Yeah bookmaking this wasn’t a terrible idea.
    Great post!

  • Comment Link view site Thursday, 30 March 2017 08:24 posted by view site

    Excellent post, you have stated some good details, I think this is a good site.

  • Comment Link Example Thursday, 30 March 2017 08:22 posted by Example

    Your article is actually informative. More than that, it is
    engaging, convincing and well-written. I would want to see even more of these types
    of wonderful writing.

  • Comment Link Tanya Thursday, 30 March 2017 08:18 posted by Tanya

    I wanted to say I appreciate you providing these
    details, you're doing an excellent job with the website...

  • Comment Link Citation Thursday, 30 March 2017 08:09 posted by Citation

    I do believe all the ideas you have presented for your article.
    They’re highly persuasive and can surely work. Still, the posts are very quick
    for beginners. Thank you for the post.

  • Comment Link quạt làm mát bằng hơi nước Thursday, 30 March 2017 08:06 posted by quạt làm mát bằng hơi nước

    You actually make it appear so easy along with your presentation however
    I in finding this matter to be really something that I
    think I'd never understand. It kind of feels too complicated and
    extremely vast for me. I'm having a look
    ahead on your subsequent publish, I will try to get the cling of it!

Leave a comment

Make sure you enter the (*) required information where indicated. HTML code is not allowed.